Description: Antibe is a commercial-stage pharmaceutical company focused on pain, inflammation and regenerative medicine. Antibe's lead drug, ATB-346, targets the global need for a safer non-steroidal anti-inflammatory drug ('NSAID') for treating chronic pain and inflammation with non-addictive medication. Antibe's subsidiary, Citagenix Inc. ('Citagenix'), is a leader in Canada in the sales and marketing of tissue regenerative products servicing the dental and orthopaedic marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix has grown a comprehensive portfolio of high-quality, branded biologics and medical devices that promote bone regeneration. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.
Home Page: www.antibethera.com
15 Prince Arthur Avenue
Toronto,
ON
M5R 1B2
Canada
Phone:
416 922 3460
Officers
| Name | Title |
|---|---|
| Mr. Daniel Marcel Legault J.D., L.L.B. | Pres, CEO, Sec. & Director |
| Dr. John Lawrence Wallace M.B.A., M.Sc., MBA, MSc, Ph.D. | Founder & Vice Chair |
| Mr. Alain Wilson M.B.A., MBA | Chief Financial Officer |
| Mr. Scott Curtis C.F.A., M.Eng | Chief Operating Officer |
| Dr. David James Vaughan Ph.D. | Chief Devel. Officer |
| Dr. Joseph Stauffer D.O., M.B.A. | Chief Medical Officer |
| Dr. Ana Stegic | Director of Clinical Operations |
| Ms. Christina Cameron B.B.A. | VP of Investor Relations |
| Mr. Philip Stern | VP of Communications |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 73.5294 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6063 |
| Price-to-Sales TTM: | 2.9586 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 37 |